10/31/14 LLY 66.33 Eli Lilly and Company $LLY Hit
Post# of 128
Posted On: 11/02/2014 1:03:10 AM
10/31/14 LLY 66.33 Eli Lilly and Company $LLY Hit a 52 week high of 67.43 Closing the day 10/31/14 at 66.33 -0.47 -0.70% With a day low of 65.91 and a total volume of 4,471,900.
LLY Recent Posts: http://investorshangout.com/Eli-Lilly-And-Company-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Veeva Systems Flies High On Cloud For Life Sciences
at Investor's Business Daily - Thu Oct 30, 4:31PM CDT
Before founding software company Veeva Systems in 2007, Peter Gassner was certain of two things. He wanted the technology to be cloud-based and to address critical issues for a specific industry. He decided to focus on life sciences. "We could have...
VEEV: 29.78 (+0.99), IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), ORCL: 39.05 (+0.55), CRM: 63.99 (+2.27), NVS: 92.69 (+0.74)
Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Oct 30, 12:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Global ADHD Drugs Market 2014-2018
M2 - Thu Oct 30, 7:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js5g8x/global_adhd_drugs) has announced the addition of the "Global ADHD Drugs Market 2014-2018" report to their offering. The Global ADHD Drugs market to grow at a CAGR of 5.33% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include: - Stimulants - Non-stimulants One key trend emerging in this market is an increase in awareness, which is helping to increase the number of treatment-seeking patients. According to the report, the major driving factor in this market is the high unmet need for appropriate drugs in the market. The current treatment options cannot cure the disorder completely, and thus market demand is high for this indication. Therefore, drugs that can cause disease remission in patients are expected to drive the market significantly. Further, the report states that the unknown etiology of the disease is a major factor that restricts the growth of the market. This makes it difficult for drug makers to identify a target that can be used to develop a medication to cure ADHD. Key Vendors - Eli Lilly - Janssen - Novartis - Shire Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Segmentation by Route of Administration - Market Segmentation by Dosage Form - Geographical Segmentation - Key Leading Countries - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/js...adhd_drugs
LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Global Peptide Therapeutics Market 2014-2018
M2 - Thu Oct 30, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2r49ld/global_peptide) has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering. The Global Peptide Therapeutics market to grow at a CAGR of 9.25% over the period 2013-2018 Peptides are amino acids sequences and among the most potent biologically active substances found in nature. Peptides are used to control, trigger, and maintain physiological processes in living beings. However, the use of peptides as therapeutic agents has always been difficult because of their inherent instability and incapability to cross cellular membranes. Peptides also entail the requirement of specific technology to tackle the extensive and challenging steps in their synthesis. Currently, there are more than 80 peptides marketed by various companies. These companies explore the probability of designing and engineering peptides that overcome their natural confines and allow these potent chemical entities to be used as therapeutic agents. One key trend upcoming in the market is the growing popularity of peptide therapeutics in the market, which results in increased consumption of peptide drugs, thereby affecting market growth. According to the report, the major driving factor of this market is the increase in patient populations suffering from various diseases in many countries. This causes an increase in the consumption of peptide medicines, thereby boosting market growth. Further, the report states that the high cost of therapy is a major challenge to the growth of the market. It results in a decrease in the rate of patients seeking treatment in the market, which restrains the growth. Key Vendors - AstraZeneca - Eli Lilly - Novo Nordisk - Sanofi Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Route of Administration - Market Segmentation by Drug Class - Market Segmentation by Technology - Geographical Segmentation - Peptide Synthesis - Optimization of Peptides - Stabilization of Peptides - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2r...al_peptide
NVO: 45.18 (-1.03), LLY: 66.33 (-0.47)
Lilly Shares Insights from Decade-Long Technology Transfer Experience
PR Newswire - Thu Oct 30, 12:00AM CDT
Today Eli Lilly and Company (NYSE: LLY) published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB). Begun in 2003, the effort included Lilly donating manufacturing technology and know-how for two antibiotics to pharmaceutical manufacturers in China, India, Russia and South Africa - all MDR-TB 'hot spots.' It also served as the foundation for the Lilly MDR-TB Partnership, the company's largest-ever philanthropic effort.
LLY: 66.33 (-0.47)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 190.06 (+0.62), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
Sanofi Axes CEO, Hit By Multiple Downgrades
at Investor's Business Daily - Wed Oct 29, 11:51AM CDT
Big French pharma Sanofi (SNY) fired its CEO Wednesday, pushing its stock down sharply for the second day in a row and sparking a slew of downgrades on Wall Street. Sanofi's (SNY) board issued a short statement saying that it had voted unanimously to...
NVO: 45.18 (-1.03), LLY: 66.33 (-0.47), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92)
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs
PR Newswire - Wed Oct 29, 11:00AM CDT
Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo (Bristol-Myers Squibb/Ono Pharmaceutical) and Keytruda (Merck & Co), and the PD-ligand-1 (PD-L1) inhibitors MDPL-3280A (Genentech/Roche/Chugai) and MEDI-4736 (AstraZeneca/MedImmune), will be the major driver of growth due to their premium price and robust uptake across treatment settings. Notably, the NSCLC market will grow despite the generic/biosimilar erosion of key branded current therapies, including Eli Lilly's Alimta, Genentech/Roche/Astellas/Chugai's Tarceva and Genentech/Roche/Chugai's Avastin.
MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Lilly to Present Record-Breaking $12.7 Million Gift to United Way
PR Newswire - Wed Oct 29, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) today will present a record-breaking gift of $12.7 million to United Way. As the company's largest United Way contribution ever, the donation represents the giving of Lilly and Elanco Animal Health employees and retirees in the United States and Puerto Rico--plus a dollar-for-dollar matching gift from the Lilly Foundation.
LLY: 66.33 (-0.47)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 112.00 (-2.22), PFE: 29.95 (+0.11), EW: 120.92 (+0.64), LLY: 66.33 (-0.47), ABBV: 63.46 (+2.28)
Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries
CNW Group - Wed Oct 29, 7:00AM CDT
In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90 percent of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance.
LLY: 66.33 (-0.47)
Imaging Agents - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkw443/imaging_agents) has announced the addition of the "Imaging Agents - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: - Contrast Media (X-Ray, MRI, & Ultrasound) - Diagnostic Radiopharmaceuticals The report profiles 52 companies including many key and niche players such as: - Bayer Healthcare Pharmaceuticals - Bracco Diagnostics, Inc. - Daiichi Sankyo Company Limited - Eisai Co., Ltd. - Eli Lilly and Company - EUSA Pharma - GE Healthcare - Guerbet Group - Lantheus Medical Imaging Inc - Mallinckrodt Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. A Segmental Review 3. Market Trends & Issues 4. Competition 5. Global Medical Imaging Market - An Overview 6. Product Overview 7. Technology Dynamics 8. Product Launches/Approvals/ Clinical Trials 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 59) - The United States (34) - Canada (1) - Japan (3) - Europe (18) - - France (1) - - Germany (4) - - The United Kingdom (3) - - Italy (2) - - Rest of Europe (
- Asia-Pacific (Excluding Japan) (2) - Africa (1) For more information visit http://www.researchandmarkets.com/research/tk...ing_agents
LLY: 66.33 (-0.47)
After Yesterday's Decline of 2.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 28, 4:13PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $63.74 to a high of $66.10. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $63.78 on volume of 8.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 66.33 (-0.47)
Eli Lilly Falls 2.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Oct 28, 4:13PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $63.74 to a high of $66.10. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $63.78 on volume of 8.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 66.33 (-0.47)
Insider Trading Alert - BTU, IPGP And LLY Traded By Insiders
at The Street - Tue Oct 28, 2:00PM CDT
Stocks with insider trader activity include BTU, IPGP and LLY
BTU: 10.43 (+0.18), LLY: 66.33 (-0.47), IPGP: 73.41 (+1.45)
French Drugmaker Sanofi Warns Of Tougher Competition
at Investor's Business Daily - Tue Oct 28, 1:42PM CDT
Stock in Sanofi fell Tuesday after the French drugmaker warned that sales of its diabetes products face a more challenging environment due to mounting competition in the U.S. The warning comes amid tension at the top of the company. On Monday, Sanofi...
NVO: 45.18 (-1.03), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), SNY: 46.24 (+0.54)
LLY Recent Posts: http://investorshangout.com/Eli-Lilly-And-Company-LLY-51689/
LLY Eli Lilly and Company Recent Headline News
Incyte Gains on Q3 Earnings and Revenue Beat, Raises View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 12:49PM CDT
Incyte (INCY) reported third-quarter 2014 earnings of 33 cents per share, beating the Zacks Consensus Estimate of 2 cents.
BIIB: 321.08 (+0.08), INCY: 67.06 (+2.88), LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Eli Lilly/Boehringer Ingelheim Restructure Diabetes Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 5:05PM CDT
Eli Lilly (LLY) and partner Boehringer Ingelheim amended the operational and financial structure of their diabetes collaboration in certain countries.
AGN: 190.06 (+0.62), ABBV: 63.46 (+2.28), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Veeva Systems Flies High On Cloud For Life Sciences
at Investor's Business Daily - Thu Oct 30, 4:31PM CDT
Before founding software company Veeva Systems in 2007, Peter Gassner was certain of two things. He wanted the technology to be cloud-based and to address critical issues for a specific industry. He decided to focus on life sciences. "We could have...
VEEV: 29.78 (+0.99), IMS: 24.25 (+0.26), GILD: 112.00 (-2.22), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), ORCL: 39.05 (+0.55), CRM: 63.99 (+2.27), NVS: 92.69 (+0.74)
Big Pharma Solid Q3 Earnings Put These ETFs in Focus - ETF News And Commentary
Sweta Killa - Zacks Investment Research - Thu Oct 30, 12:00PM CDT
Pharma ETFs have been surging over the past one week buoyed by solid earnings from big industry players.
IHE: 145.99 (-0.68), JNJ: 107.78 (+0.74), PPH: 63.38 (+0.22), PJP: 68.69 (+0.02), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Global ADHD Drugs Market 2014-2018
M2 - Thu Oct 30, 7:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/js5g8x/global_adhd_drugs) has announced the addition of the "Global ADHD Drugs Market 2014-2018" report to their offering. The Global ADHD Drugs market to grow at a CAGR of 5.33% over the period 2013-2018 This report covers the present scenario and the growth prospects of the Global ADHD Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various therapies used in the treatment of ADHD, which include: - Stimulants - Non-stimulants One key trend emerging in this market is an increase in awareness, which is helping to increase the number of treatment-seeking patients. According to the report, the major driving factor in this market is the high unmet need for appropriate drugs in the market. The current treatment options cannot cure the disorder completely, and thus market demand is high for this indication. Therefore, drugs that can cause disease remission in patients are expected to drive the market significantly. Further, the report states that the unknown etiology of the disease is a major factor that restricts the growth of the market. This makes it difficult for drug makers to identify a target that can be used to develop a medication to cure ADHD. Key Vendors - Eli Lilly - Janssen - Novartis - Shire Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Product Profiles - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Segmentation by Route of Administration - Market Segmentation by Dosage Form - Geographical Segmentation - Key Leading Countries - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/js...adhd_drugs
LLY: 66.33 (-0.47), NVS: 92.69 (+0.74)
Global Peptide Therapeutics Market 2014-2018
M2 - Thu Oct 30, 6:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2r49ld/global_peptide) has announced the addition of the "Global Peptide Therapeutics Market 2014-2018" report to their offering. The Global Peptide Therapeutics market to grow at a CAGR of 9.25% over the period 2013-2018 Peptides are amino acids sequences and among the most potent biologically active substances found in nature. Peptides are used to control, trigger, and maintain physiological processes in living beings. However, the use of peptides as therapeutic agents has always been difficult because of their inherent instability and incapability to cross cellular membranes. Peptides also entail the requirement of specific technology to tackle the extensive and challenging steps in their synthesis. Currently, there are more than 80 peptides marketed by various companies. These companies explore the probability of designing and engineering peptides that overcome their natural confines and allow these potent chemical entities to be used as therapeutic agents. One key trend upcoming in the market is the growing popularity of peptide therapeutics in the market, which results in increased consumption of peptide drugs, thereby affecting market growth. According to the report, the major driving factor of this market is the increase in patient populations suffering from various diseases in many countries. This causes an increase in the consumption of peptide medicines, thereby boosting market growth. Further, the report states that the high cost of therapy is a major challenge to the growth of the market. It results in a decrease in the rate of patients seeking treatment in the market, which restrains the growth. Key Vendors - AstraZeneca - Eli Lilly - Novo Nordisk - Sanofi Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Route of Administration - Market Segmentation by Drug Class - Market Segmentation by Technology - Geographical Segmentation - Peptide Synthesis - Optimization of Peptides - Stabilization of Peptides - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Pipeline Portfolio - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2r...al_peptide
NVO: 45.18 (-1.03), LLY: 66.33 (-0.47)
Lilly Shares Insights from Decade-Long Technology Transfer Experience
PR Newswire - Thu Oct 30, 12:00AM CDT
Today Eli Lilly and Company (NYSE: LLY) published details of its long-standing technology transfer program to increase the global supply of medicines for multidrug-resistant tuberculosis (MDR-TB). Begun in 2003, the effort included Lilly donating manufacturing technology and know-how for two antibiotics to pharmaceutical manufacturers in China, India, Russia and South Africa - all MDR-TB 'hot spots.' It also served as the foundation for the Lilly MDR-TB Partnership, the company's largest-ever philanthropic effort.
LLY: 66.33 (-0.47)
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 1:04PM CDT
Novartis reported core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
AGN: 190.06 (+0.62), LLY: 66.33 (-0.47), GSK: 45.49 (+0.35), NVS: 92.69 (+0.74)
Sanofi Axes CEO, Hit By Multiple Downgrades
at Investor's Business Daily - Wed Oct 29, 11:51AM CDT
Big French pharma Sanofi (SNY) fired its CEO Wednesday, pushing its stock down sharply for the second day in a row and sparking a slew of downgrades on Wall Street. Sanofi's (SNY) board issued a short statement saying that it had voted unanimously to...
NVO: 45.18 (-1.03), LLY: 66.33 (-0.47), SNY: 46.24 (+0.54), REGN: 393.72 (+0.92)
The Market for Non-Small-Cell Lung Cancer Will Grow to $8.5 Billion in 2023, Driven by the Entry of Thirteen Novel Drugs
PR Newswire - Wed Oct 29, 11:00AM CDT
Decision Resources Group finds that the entry of 13 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.2 billion in 2013 to $8.5 billion in 2023. The entry of four immune checkpoint inhibitors, namely the programmed death-1 (PD-1) inhibitors Opdivo (Bristol-Myers Squibb/Ono Pharmaceutical) and Keytruda (Merck & Co), and the PD-ligand-1 (PD-L1) inhibitors MDPL-3280A (Genentech/Roche/Chugai) and MEDI-4736 (AstraZeneca/MedImmune), will be the major driver of growth due to their premium price and robust uptake across treatment settings. Notably, the NSCLC market will grow despite the generic/biosimilar erosion of key branded current therapies, including Eli Lilly's Alimta, Genentech/Roche/Astellas/Chugai's Tarceva and Genentech/Roche/Chugai's Avastin.
MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), BMY: 58.19 (-0.79)
Lilly to Present Record-Breaking $12.7 Million Gift to United Way
PR Newswire - Wed Oct 29, 8:00AM CDT
Eli Lilly and Company (NYSE: LLY) today will present a record-breaking gift of $12.7 million to United Way. As the company's largest United Way contribution ever, the donation represents the giving of Lilly and Elanco Animal Health employees and retirees in the United States and Puerto Rico--plus a dollar-for-dollar matching gift from the Lilly Foundation.
LLY: 66.33 (-0.47)
Compliance Notice, Dividend Announcements, New Share Repurchase Program, and Financial Results - Research Reports on Gilead, Pfizer, AbbVie, Edwards and Lilly
PR Newswire - Wed Oct 29, 7:35AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Edwards Lifesciences Corp. (NYSE: EW) and Eli Lilly and Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7520-100free.
GILD: 112.00 (-2.22), PFE: 29.95 (+0.11), EW: 120.92 (+0.64), LLY: 66.33 (-0.47), ABBV: 63.46 (+2.28)
Boehringer Ingelheim and Lilly Revising Operational Structure of Diabetes Alliance in Certain Countries
CNW Group - Wed Oct 29, 7:00AM CDT
In a move that will strengthen their alliance by enhancing efficiencies and enabling greater focus on product launches, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) are changing the operational and financial structure of their diabetes alliance in certain countries. Under the revised agreement, 17 countries representing more than 90 percent of the alliance's anticipated market opportunity will continue their co-promotion work. In all other countries, the companies will exclusively commercialize the respective molecules they brought to the alliance.
LLY: 66.33 (-0.47)
Imaging Agents - 2014 Global Strategic Business Report
M2 - Wed Oct 29, 6:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tkw443/imaging_agents) has announced the addition of the "Imaging Agents - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Middle East, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. This report analyzes the worldwide markets for Imaging Agents in US$ by the following Product Segments: - Contrast Media (X-Ray, MRI, & Ultrasound) - Diagnostic Radiopharmaceuticals The report profiles 52 companies including many key and niche players such as: - Bayer Healthcare Pharmaceuticals - Bracco Diagnostics, Inc. - Daiichi Sankyo Company Limited - Eisai Co., Ltd. - Eli Lilly and Company - EUSA Pharma - GE Healthcare - Guerbet Group - Lantheus Medical Imaging Inc - Mallinckrodt Pharmaceuticals Key Topics Covered: I. Introduction, Methodology & Product Definitions II. Executive Summary 1. Industry Overview 2. A Segmental Review 3. Market Trends & Issues 4. Competition 5. Global Medical Imaging Market - An Overview 6. Product Overview 7. Technology Dynamics 8. Product Launches/Approvals/ Clinical Trials 9. Recent Industry Activity 10. Focus On Select Players 11. Global Market Perspective III. Market 1. The United States 2. Canada 3. Japan 4. Europe 5. Asia-Pacific 6. The Middle East 7. Latin America IV. Competitive Landscape Total Companies Profiled: 52 (including Divisions/Subsidiaries - 59) - The United States (34) - Canada (1) - Japan (3) - Europe (18) - - France (1) - - Germany (4) - - The United Kingdom (3) - - Italy (2) - - Rest of Europe (
- Asia-Pacific (Excluding Japan) (2) - Africa (1) For more information visit http://www.researchandmarkets.com/research/tk...ing_agents LLY: 66.33 (-0.47)
After Yesterday's Decline of 2.07%, Eli Lilly Offers Investors Better Value
Comtex SmarTrend(R) - Tue Oct 28, 4:13PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $63.74 to a high of $66.10. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $63.78 on volume of 8.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 66.33 (-0.47)
Eli Lilly Falls 2.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Oct 28, 4:13PM CDT
Eli Lilly (NYSE:LLY) traded in a range yesterday that spanned from a low of $63.74 to a high of $66.10. Yesterday, the shares fell 2.1%, which took the trading range below the 3-day low of $63.78 on volume of 8.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LLY: 66.33 (-0.47)
Insider Trading Alert - BTU, IPGP And LLY Traded By Insiders
at The Street - Tue Oct 28, 2:00PM CDT
Stocks with insider trader activity include BTU, IPGP and LLY
BTU: 10.43 (+0.18), LLY: 66.33 (-0.47), IPGP: 73.41 (+1.45)
French Drugmaker Sanofi Warns Of Tougher Competition
at Investor's Business Daily - Tue Oct 28, 1:42PM CDT
Stock in Sanofi fell Tuesday after the French drugmaker warned that sales of its diabetes products face a more challenging environment due to mounting competition in the U.S. The warning comes amid tension at the top of the company. On Monday, Sanofi...
NVO: 45.18 (-1.03), MRK: 57.94 (+0.63), LLY: 66.33 (-0.47), SNY: 46.24 (+0.54)
(0)
(0)Eli Lilly & Co. (LLY) Stock Research Links
Scroll down for more posts ▼